Kabra Drugs logo

Kabra Drugs financials: balance sheet, profit and loss, cash flow

BSE: 524322Pharmaceuticals & BiotechnologySmall Cap

Kabra Drugs Ltd · Face value ₹10 · Listed Jul 1993
Last close ₹16.26up ₹0.40 (2.52%)

Share price at the BSE close on 28 Oct 2026. Previous close ₹15.86.

28 Oct: open ₹16.80, high ₹16.80, low ₹15.30

52-week range of traded prices to 28 Oct 2026
₹15.30Low, 28 Oct 2026₹35.52High, 11 Feb 2026
Market cap
₹39 Cr3,225th largest listed
P/E
5.08
P/B
1.30
Dividend yield
Nonein the last 12 months
ROE
28.0%
ROCE
28.4%
Debt to equity
0.01
Volume, BSE
21,705

Kabra Drugs' financial statements for the 10 years to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

10 years at a glance

₹ crore, years to March.Kabra Drugs annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
7.70.0Mar 172.0−2.4Mar 1800.00.7Mar 190.0−0.1Mar 200−0.20.9Mar 210−0.21.0Mar 220−0.31.4Mar 230−0.71.7Mar 240−1.10.4Mar 25935.00.4Mar 26
Peak revenue ₹93 Cr, year to Mar 2026; lowest ₹0.00 Cr, year to Mar 2019Back to profit in the year to Mar 2026, ₹4.96 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin
5.7%−260.9%5.7%−51.5%−115.7%5.7%0.5%−117.4%−260.9%5.3%Mar 17Mar 19Mar 21Mar 23Mar 25Mar 26

From Apr 2019 leases sit on the balance sheet: rent is charged as depreciation and interest instead, so operating profit and total assets step up with nothing about the business having changed. Borrowings here leave lease liabilities out. Lease payments were 2.3% of operating profit in the first full year.

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue93
  2. Materials and goods−84
  3. Employee costs−1.5
  4. Other expenses−2.3
  5. Operating profit5.3
  6. Depreciation−0.1
  7. Other income+0.5
  8. One-off items0.0
  9. Finance costs0.0
  10. Profit before tax5.7
  11. Tax−0.8
  12. Net profit5.0

What the company owns

  • Receivables₹71 Cr
  • Cash and bank₹11 Cr
  • Plant, investments and other assets₹5 Cr

What pays for it: net worth and liabilities

  • Owed to suppliers₹55 Cr
  • Net worth₹30 Cr
  • Other liabilities₹1 Cr
  • Borrowings₹0 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Kabra Drugs quarterly results

₹ croreMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 MayJun 2026Twelve monthsFiled 12 Aug
Revenue from operations82000000093132
73000001287123
Materials and goods bought510–0000084120
Employee costs110–0000111
Other expenses210–0000122
Operating profit before depreciation0−100000−1−259
Operating margin5.7%−51.5%–−115.7%–––––5.7%6.5%
Materials, % of revenue62.3%63.6%–––––––90.2%91.0%
Employee costs, % of revenue9.7%58.6%–––––––1.6%1.0%
Other expenses, % of revenue22.3%29.2%–––––––2.5%1.5%
Depreciation and amortisation00000000000
Operating profit after depreciation0−100000−1−259
Other income00000000101
Finance costs00000000000
Profit before one-off items and tax0−100000−1−169
One-off items–−10–0000000
Profit before tax0−200000−1−169
0–0–000001–
Net profit0−200000−1−158
Net margin0.5%−117.4%–−260.9%–––––5.3%5.8%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the year to Mar 2020 they do not, so they are left blank.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
0.2–−0.2−0.4−0.71.124.729.6
Share capital4.4–4.44.44.44.423.723.7
Reserves−4.2–−4.6−4.8−5.1−3.30.95.9
0.7–0.91.01.41.70.40.4
1.5–1.61.10.13.50.656.5
0.0–0.00.01.40.00.00.1
Total assets1.7–1.40.70.74.625.286.3
0.2–0.00.00.00.00.12.2
1.5–1.40.70.74.525.284.1
Net debt0.5–0.91.01.4−1.0−20.9−10.2
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2020, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
−0.2−0.1−0.4−0.2−4.7−9.5
−0.10.00.00.5−3.6−14.8
Receivables0.00.70.00.00.0−70.2
Payables0.0−0.20.00.00.054.8
Other working capital−0.1−0.40.00.5−3.60.5
Capital spending0.00.00.00.00.10.7
Free cash flow−0.2−0.1−0.4−0.2−4.8−10.2
0.00.00.00.0−0.1−1.4
0.20.10.42.923.40.1
Dividends paid0.00.00.00.00.00.0
Shares bought back0.00.00.00.00.00.0
Shares issued0.00.00.02.624.70.0
Net change in cash0.00.00.02.718.6−10.7
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Earnings per share₹0.09−₹5.37−₹0.02−₹0.14−₹0.41−₹0.42−₹0.77−₹1.68−₹0.99₹2.09
Diluted earnings per share₹0.09−₹5.37−₹0.02−₹0.14−₹0.41−₹0.42−₹0.77−₹1.68−₹0.99₹2.09
Book value per share––₹0.43–−₹0.47−₹0.90−₹1.67₹2.47₹10.40₹12.49
Shareholder yield–––––0.0%0.0%−80.8%−220.8%0.0%
Market cap at the year end (₹ crore)2.81.40.21.4–2.02.43.211.258.3

Ratios

Standalone, years to March.Kabra Drugs PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Filed 29 May
Revenue growth–−73.9%−100.0%–−100.0%–––––
Return on equity–––––––––18.3%
Return on capital employed––−1.0%–−26.0%−29.3%−52.9%−26.4%−6.9%17.5%
Cash conversion–––––––––−191.0%
Interest cover1.2––––––––175.3
Debt to equity––3.53––––1.580.020.01
Receivable days–––––––––279
Inventory days–––––––––0
Payable days–––––––––239
Cash conversion cycle, days–––––––––39
Working capital days–––––––––68
Asset turnover––0.00–0.000.000.000.000.001.66
Assets per rupee of net worth––8.97–−6.75−3.55−1.2814.991.162.05
Sales per rupee of plant––0.00–0.00–––0.00132.07
Capital spending to depreciation––––0.000.00––7.039.87
Plant being built, % of plant in use––0.0%–0.0%–––––
Interest cover is left blank for the years to Mar 2018 and Mar 2020: operating profit after depreciation is a loss, and a loss covers no interest bill. Debt to equity is left blank for the years to Mar 2021, Mar 2022 and Mar 2023: net worth is below zero, so there is no shareholders' money to set the borrowings against. No balance sheet is on record for the years to Mar 2017, Mar 2018 and Mar 2020, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
8.9%
Cash from operations against operating profit
−177.8%
Measure5 years3 years
Return on capital employed, average−19.6%−5.2%
Asset turnover, average0.330.55
Debt to equity, average–0.54

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations−14.9−14.4−9.5
Cash from investing−1.4−1.4−1.4
Cash from financing26.926.40.1
Capital spending0.80.80.7
Dividends paid0.00.00.0
Shares bought back0.00.00.0
Shares issued for cash27.227.20.0
Borrowings raised0.80.30.0
Borrowings repaid1.31.30.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Altman Z-scorePublished threshold 1.81––−3.42––−9.63−9.68−0.72–2.39
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets–––––−4.842.30−20.0024.6528.33
Cash from operations to profit, 3 yearsPublished threshold 0.7 times–––––––––−4.59
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––––––––−0.56
Effective tax ratePublished threshold 17.16 per cent17.39––––––––13.30
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––––––13.30
A threshold marked as ours has no published figure; it is the line we read the check against.